|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||20.01 - 26.00|
|52-week range||2.84 - 45.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||14 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shares of Longeveron (NASDAQ: LGVN) jumped 661.2% in November, according to data from S&P Global Market Intelligence. The stock surged after it was announced that the company received a Rare Pediatric Disease (RPD) designation for its Lomecel-B treatment. Longeveron announced on Nov. 18 that Lomecel-B had received RPD designation for the treatment of hypoplastic left heart syndrome (HLHS) -- a potentially fatally heart condition in infants.
An American biotechnology company located in Miami of all places has convinced more than a few investors that its cellular therapy candidate can reverse common effects of aging. This November, shares of Longeveron (NASDAQ: LGVN) shot up more than 10-fold. Investors who missed the boat the first time around are wondering if Longeveron the recent slide is an opportunity to buy a potential long-term winner at a relative discount.
An orphan drug designation for the treatment of a rare heart condition is pushing the biotech stock higher.